OBJECTIVE: The cancer anorexia/weight loss syndrome commonly occurs in patients with non-small cell lung cancer (NSCLC) and is characterized by loss of weight and appetite as well as diminished survival. The current study explored whether any of 22 single nucleotide polymorphisms (SNPs) of certain previously implicated inflammatory cytokines (interleukin-1 beta, interleukin-1RN, interleukin-6, and tumor necrosis factor) are associated with this syndrome. PATIENTS AND METHODS: All NSCLC patients who had been enrolled in the Mayo Clinic Lung Cancer Cohort, had completed a health-related questionnaire approximately 6 months after enrollment, and had blood drawn were included in this study, thus yielding a sample size of 471 patients. RESULTS: Sixty-six (14%) patients manifested weight loss shortly after diagnosis, and 152 (32%) reported appetite loss. Only tumor necrosis factor alpha rs800629 was associated with anorexia (odds ratio: 0.46; 95% confidence interval: 0.29, 0.72; p < 0.001); patients who were heterozygous and minor homozygous were less likely to suffer anorexia. Otherwise, there were no statistically significant associations between any of the other 21 SNPs and weight loss and/or anorexia. In univariate analyses, weight loss, anorexia, more advanced cancer stage, and interleukin-1 beta rs1143627 were associated with a worse survival, and interleukin-6 rs2069835 was associated with better survival. However, in multivariate analyses, cancer stage and patient age were the only statistically significant predictors of worse survival. CONCLUSION: No specific SNP was associated with all aspects of the cancer anorexia/weight loss syndrome, but rs800629 may merit further study in cancer-associated anorexia.
OBJECTIVE: The cancer anorexia/weight loss syndrome commonly occurs in patients with non-small cell lung cancer (NSCLC) and is characterized by loss of weight and appetite as well as diminished survival. The current study explored whether any of 22 single nucleotide polymorphisms (SNPs) of certain previously implicated inflammatory cytokines (interleukin-1 beta, interleukin-1RN, interleukin-6, and tumor necrosis factor) are associated with this syndrome. PATIENTS AND METHODS: All NSCLCpatients who had been enrolled in the Mayo Clinic Lung Cancer Cohort, had completed a health-related questionnaire approximately 6 months after enrollment, and had blood drawn were included in this study, thus yielding a sample size of 471 patients. RESULTS: Sixty-six (14%) patients manifested weight loss shortly after diagnosis, and 152 (32%) reported appetite loss. Only tumor necrosis factor alphars800629 was associated with anorexia (odds ratio: 0.46; 95% confidence interval: 0.29, 0.72; p < 0.001); patients who were heterozygous and minor homozygous were less likely to suffer anorexia. Otherwise, there were no statistically significant associations between any of the other 21 SNPs and weight loss and/or anorexia. In univariate analyses, weight loss, anorexia, more advanced cancer stage, and interleukin-1 betars1143627 were associated with a worse survival, and interleukin-6rs2069835 was associated with better survival. However, in multivariate analyses, cancer stage and patient age were the only statistically significant predictors of worse survival. CONCLUSION: No specific SNP was associated with all aspects of the cancer anorexia/weight loss syndrome, but rs800629 may merit further study in cancer-associated anorexia.
Authors: F Bozzetti; C Gavazzi; R Miceli; N Rossi; L Mariani; L Cozzaglio; G Bonfanti; S Piacenza Journal: JPEN J Parenter Enteral Nutr Date: 2000 Jan-Feb Impact factor: 4.016
Authors: C L Loprinzi; N M Ellison; D J Schaid; J E Krook; L M Athmann; A M Dose; J A Mailliard; P S Johnson; L P Ebbert; L H Geeraerts Journal: J Natl Cancer Inst Date: 1990-07-04 Impact factor: 13.506
Authors: Aminah Jatoi; James Egner; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; Shaker R Dakhil; James A Mailliard; George G Klee; James E Krook Journal: Support Care Cancer Date: 2004-09 Impact factor: 3.603
Authors: C L Loprinzi; J A Laurie; H S Wieand; J E Krook; P J Novotny; J W Kugler; J Bartel; M Law; M Bateman; N E Klatt Journal: J Clin Oncol Date: 1994-03 Impact factor: 44.544
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: William F Pirl; Lara Traeger; Joseph A Greer; Heather Bemis; Emily Gallagher; Inga Lennes; Lecia Sequist; Rebecca Heist; Jennifer S Temel Journal: Oncologist Date: 2011-08-01
Authors: N Johns; B H Tan; M MacMillan; T S Solheim; J A Ross; V E Baracos; S Damaraju; K C H Fearon Journal: J Genet Date: 2014-12 Impact factor: 1.166
Authors: Benjamin H L Tan; Torill Fladvad; Theodore P Braun; Antonio Vigano; Florian Strasser; D A Christopher Deans; Richard J E Skipworth; Tora S Solheim; Sambasivarao Damaraju; James A Ross; Stein Kaasa; Daniel L Marks; Vickie E Baracos; Frank Skorpen; Kenneth C H Fearon Journal: EMBO Mol Med Date: 2012-04-04 Impact factor: 12.137
Authors: Jennifer F Ma; Brenda J Sanchez; Derek T Hall; Anne-Marie K Tremblay; Sergio Di Marco; Imed-Eddine Gallouzi Journal: EMBO Mol Med Date: 2017-05 Impact factor: 12.137